133 results on '"Jansen, Marnix"'
Search Results
2. 223 IMMUNE CELL PHENOTYPING IN BARRETT'S ESOPHAGUS IN PATIENTS PRIOR AND AT TIME OF PROGRESSION
3. Deep Learning for Histopathological Assessment of Esophageal Adenocarcinoma Precursor Lesions
4. Poor Diagnostic Reproducibility in the Identification of Nonconventional Dysplasia in Colitis Impacts the Application of Histologic Stratification Tools
5. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia
6. Hepatocytes undergo punctuated expansion dynamics from a periportal stem cell niche in normal human liver
7. The co-evolution of the genome and epigenome in colorectal cancer
8. Phenotypic plasticity and genetic control in colorectal cancer evolution
9. Multi-scale Deformable Transformer for the Classification of Gastric Glands: The IMGL Dataset
10. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.
11. Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies
12. Immunosuppressive niche engineering at the onset of human colorectal cancer
13. Risk of metastasis among patients diagnosed with high-risk T1 esophageal adenocarcinoma who underwent endoscopic follow-up.
14. Vertical tumor-positive resection margins and the risk of residual neoplasia after endoscopic resection of Barrett's neoplasia: a nationwide cohort with pathology reassessment.
15. Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY)
16. Multi-scale Deformable Transformer for the Classification of Gastric Glands: The IMGL Dataset
17. Epigenome and early selection determine the tumour-immune evolutionary trajectory of colorectal cancer
18. Poor diagnostic reproducibility in the identification of non-conventional dysplasia in colitis impacts the application of histological stratification tools
19. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
20. 300. ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ESOPHAGEAL ADENOCARCINOMA: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
21. The Role of Serum S100B as a Clinical Follow-up Tool for Disease Recurrence in Stage III Melanoma Patients
22. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma
23. Abstract 4539: Tumor evolution and immune microenvironment dynamics define response to neoadjuvant treatment of esophageal adenocarcinoma
24. Figure S2 from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
25. Supplemental methods and tables from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
26. Supplementary Information from Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
27. A digital pathology workflow for the segmentation and classification of gastric glands: Study of gastric atrophy and intestinal metaplasia cases
28. Gland segmentation in gastric histology images: detection of intestinal metaplasia
29. Analysis of metastases rates during follow-up after endoscopic resection of early “high-risk” esophageal adenocarcinoma
30. The Need for Routine Native Nephrectomy in the Workup for Kidney Transplantation in Autosomal Dominant Polycystic Kidney Disease Patients
31. ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: EARLY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
32. P110 Cytosponge for risk stratification in patients with Barrett’s oesophagus overdue endoscopic surveillance due to COVID-19
33. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.
34. Mo1164: UTILISATION OF THE CYTOSPONGE DEVICE AS A TOOL FOR RISK STRATIFICATION IN PATIENTS WITH BARRETT'S OESOPHAGUS WHO ARE OVERDUE ENDOSCOPIC SURVEILLANCE DUE TO THE COVID-19 PANDEMIC
35. Clonal Transitions and Phenotypic Evolution in Barrett’s Esophagus
36. The Need for Routine Native Nephrectomy in the Workup for Kidney Transplantation in Autosomal Dominant Polycystic Kidney Disease Patients.
37. Histopathology-led quality evaluation of endoluminal excision specimens – not a bad idea!
38. Three-dimensional tumour microenvironment reconstruction and tumour-immune interactions' analysis
39. HFR-1 Cytosponge as a risk stratification tool in patients overdue barrett’s surveillance due to Covid-19
40. Endoscopic tissue sampling – Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline
41. Extension of early esophageal squamous cell neoplasia into ducts and submucosal glands and the role of endoscopic ablation therapy
42. Tertiary lymphoid structures (TLS) identification and density assessment on H&E-stained digital slides of lung cancer
43. Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline
44. The co-evolution of the genome and epigenome in colorectal cancer
45. ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: INTERIM RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
46. LIMITED RISK OF RESIDUAL CANCER AFTER ENDOSCOPIC RESECTION OF EARLY BARRETT'S NEOPLASIA WITH CONFIRMED VERTICAL R1 MARGIN: A NATIONWIDE COHORT IN THE NETHERLANDS
47. 253e IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
48. Tu1269 DEEP GLAND PHENOTYPING IN BARRETT'S ESOPHAGUS GLANDS REVEALS POTENTIAL BIOMARKERS OF CANCER RISK
49. Tu1286 LONG-TERM OUTCOMES OF PATIENTS FOLLOWING ENDOSCOPIC RESECTION FOR HIGH RISK T1A AND T1B OESOPHAGEAL ADENOCARCINOMA
50. Tu1280 GLAND PHENOTYPIC DIVERSITY OVER TIME AND SPACE AS A PREDICTOR OF PROGRESSION TO DYSPLASIA IN BARRETT'S ESOPHAGUS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.